Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (5372)	9/22/1998 12:15:00 PM
From: Vector1	Read Replies (2) \| Respond to of 6136

Oliver, It is impossible to catch the low tick all the time. My view is to only try and buy stocks that are undervalued by 25% or more with potential to more than triple the money invested in 4 years. I buy on fundamentals but always save room to buy more. Biotechs often have glitches which are exagerated by the market. With AGPH I purchased my first block at $31, then 29, 25 and 22.5. Assuming Viracept continues its momentum and any one of the drugs in clinic are successful AGPH could be a $100 stock in 3 to 4 years. If Remmune is successful in the clinic and gets FDA approval it will certainly crack $100. V1